News
-
VistaGen Therapeutics said that the FDA has agreed to details of a proposed Phase 3 trial of the company’s PH94B aloradine nasal spray for the treatment of social anxiety disorder (SAD). PH94B was granted Fast Track… Read more . . .
-
Health Canada has issued a Notice of Compliance for Janssen Pharmaceutical’s Spravato esketamine nasal spray for the treatment of major depressive disorder, and the product is now available to Canadian patients, the company said. Spravato… Read more . . .
-
MannKind Corporation has announced the appointment of Alejandro Galindo as Chief Commercial Officer. Galindo most recently headed the Intensive Insulin Management business unit at Medtronic and previously served in a number of roles at GE Healthcare.… Read more . . .
-
Synairgen has announced that a Phase 2 clinical trial of its SNG001 nebulized interferon-beta-1a demonstrated that hospitalized COVID-19 patients receiving the drug were two times more likely to recover over the course of treatment; had… Read more . . .
-
Verona Pharma announced that it has raised approximately $200 million in a private placement, with net proceeds of ~$183 million to be used for Phase 3 development of nebulized ensifentrine for the treatment of COPD.… Read more . . .
-
Atossa Therapeutics said that preclinical testing of its AT-301 nasal spray in VERO cells has demonstrated that it can limit SARS-CoV-2 infectivity, and the company has contracted with Australian CRO Advance Clinical for a Phase… Read more . . .
-
According to the UK’s Medicines & Healthcare products Regulatory Agency (MHRA), Ferring Pharmaceuticals has recalled multiple batches of Desmospray 0.1 mg/ml desmopressin, Aspire branded desmopressin 0.1 mg/ml, and Octim desmopressin 1.5 mg/ml nasal sprays “due… Read more . . .
-
Submit RDD Europe 2021 speaker and workshop proposals by August 1, 2020. For podium presentations, submit a 200-word summary at https://www.rddonline.com/rdd/speaker_reg.php?id=20 For company-sponsored workshops, submit proposals at https://www.rddonline.com/rdd/workshop_reg.php?id=20 At this time, program topics for the… Read more . . .
-
Nephron Pharmaceuticals said that it has hired Rita Boucher as Chief Quality Officer and is promoting Jamie Shuster to Chief Projects Officer and Stephanie Simmonds to Chief Clinical Officer. Boucher previously worked in quality assurance… Read more . . .
-
Altimmune has announced that a study of its AdCOVID intranasal vaccine candidate induced a strong immune response in a mouse model. The results support advancing AdCOVID into a Phase 1 development, the company said, and… Read more . . .

Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
May 30-June 2: ISAM Congress 2027, Dublin, Ireland
June 23: SMI London, London, UK


